Lyra Therapeutics (OTCMKTS:LYRA – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Lyra Therapeutics to related businesses based on the strength of its institutional ownership, analyst recommendations, risk, dividends, valuation, profitability and earnings.
Profitability
This table compares Lyra Therapeutics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lyra Therapeutics | N/A | N/A | N/A |
| Lyra Therapeutics Competitors | -2,391.71% | -204.89% | -14.89% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Lyra Therapeutics and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lyra Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Lyra Therapeutics Competitors | 7870 | 13817 | 25857 | 1043 | 2.41 |
Volatility & Risk
Lyra Therapeutics has a beta of -0.29, suggesting that its stock price is 129% less volatile than the S&P 500. Comparatively, Lyra Therapeutics’ rivals have a beta of -0.05, suggesting that their average stock price is 105% less volatile than the S&P 500.
Institutional & Insider Ownership
95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.3% of Lyra Therapeutics shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Lyra Therapeutics and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Lyra Therapeutics | $400,000.00 | -$28.92 million | -0.00 |
| Lyra Therapeutics Competitors | $17.31 billion | $3.17 billion | 560.54 |
Lyra Therapeutics’ rivals have higher revenue and earnings than Lyra Therapeutics. Lyra Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Summary
Lyra Therapeutics rivals beat Lyra Therapeutics on 9 of the 13 factors compared.
About Lyra Therapeutics
Lyra Therapeutics is a U.S.-based biotechnology company that has focused on developing localized treatments for chronic rhinosinusitis, a long-lasting inflammatory condition affecting the nose and sinuses. The company’s investigational candidates, LYR-210 and LYR-220, are bioabsorbable implants designed to deliver mometasone furoate, a corticosteroid, directly to nasal and sinus tissues over an extended period. The treatments were developed for administration by a health care provider, with the goal of providing sustained therapy without relying solely on daily medication.
Receive News & Ratings for Lyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
